Nasdaq compliance follows positive upward trend in Company’s Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disc ...

In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro™ treatment over placebo was observed in cognitive, behavioral and biological endpoints. Treatment with XPro™ was well-tolerated and safe, eve ...

CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease will be presented in poster session at the upcoming Adv ...

June 24, 2025 7:00 AM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential a ...

Greetings everyone. A few years ago, we were wrapping up a vacation in Hawaii. It's a family vacation at the airport, bags in hand.I suddenly realized, oh my god, I left our passports at the hotel. Okay, happens once in a while, right. And later on, I started forgetting the names of the people I would interact with.You know, it didn't happen every day, but noticeable enough. It was there. And I asked my neurology friend, "Hey, what if this happens to me every day? I start forgetting things that normally I d ...

Ventyx Biosciences (VTYX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Don't worry, we would not miss this. Speaker1 Never a doubt, Mike. Speaker0 Good afternoon. I'm Michael Yee, a biotechnology analyst here at Jefferies. And very happy to moderate our next discussion with Ventix Biosciences. We have members of the of the team up here. We have Raju Mohan, CEO, and Matt Moore. Matt Moore. Fantastic. Maybe it would be a great opportunity, Raju, for you to just make some, broad opening comments. Ventix ...

Reviva Pharmaceuticals Holdings (RVPH) Update / Briefing June 02, 2025 08:00 AM ET Speaker0 As a reminder, this call is being recorded, and a replay will be made available on the Reviva website following the conclusion of the event. I'd now like to turn the call over to doctor Lax Bhatt, founder, president, and chief executive officer of Reviva Pharmaceuticals. Please go ahead, Lax. Speaker1 Thank you, Tara. So good morning, everyone. My name is Lax Bart. I am the founder, president, and CEO of Reviva Pharm ...

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST. A live webcast of the event can be accessed ...

Financial Data and Key Metrics Changes - COYA Therapeutics is publicly traded on NASDAQ under the ticker symbol COYA, with a buy rating and a twelve-month price target of $18 per share [2] - The company anticipates receiving $8.4 million upon IND approval and trial initiation, with a total deal value of $700 million from the partnership with Dr. Reddy's [18][19] Business Line Data and Key Metrics Changes - The primary focus is on neuroinflammation, which is believed to drive the progression of neurodegenerative diseases [4] - COYA's lead asset, COIA-302, is prioritized for ALS, with an IND filing expected by the end of the current quarter and a Phase IIb trial planned [11][12] Market Data and Key Metrics Changes - The company is targeting niche orphan indications like ALS and frontotemporal dementia, while also pursuing mass market indications like Alzheimer's [9] - The current landscape for ALS trials has become more favorable for recruitment due to the withdrawal of other products, which has created enthusiasm among trial sites [20][22] Company Strategy and Development Direction - COYA aims to maximize value by pursuing both niche and broader market opportunities, with a focus on ALS and frontotemporal dementia for regulatory flexibility [10] - The company plans to continue generating data in frontotemporal dementia and Alzheimer's, while also exploring strategic partnerships to enhance its market position [43][45] Management's Comments on Operating Environment and Future Outlook - Management believes that the FDA remains receptive to ALS drug approvals if data supports it, despite recent challenges in the market [21][23] - The company is confident in its approach to neuroinflammation and its potential to address unmet needs in Alzheimer's disease, which is characterized by a lack of effective treatments [30][31] Other Important Information - COYA is developing a regulatory T cell-derived exosome platform aimed at treating systemic and neurodegenerative diseases driven by chronic neuroinflammation, which complements its existing programs [40][42] - The partnership with Dr. Reddy's provides COYA with a strategic advantage and a steady line of sight to non-dilutive funding [45] Q&A Session Summary Question: What is the current focus for COYA Therapeutics? - The immediate focus is on filing for ALS and starting the ALS study, which is expected to be a significant value driver [43] Question: How has the regulatory environment changed for ALS? - There has been no communicated change from the FDA, and recruitment for ALS trials is expected to be easier due to fewer ongoing trials [21][22] Question: What are the expected outcomes for future clinical development? - Relevant outcome measures will include Treg function and cognitive scales, with a focus on stabilizing or improving cognition in Alzheimer's patients [36][38]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]